211 related articles for article (PubMed ID: 37888980)
1. V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins.
Anang S; Zhang S; Fritschi C; Chiu T-J; Yang D; Smith Iii AB; Madani N; Sodroski J
J Virol; 2023 Nov; 97(11):e0117123. PubMed ID: 37888980
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
Anang S; Richard J; Bourassa C; Goyette G; Chiu TJ; Chen HC; Smith AB; Madani N; Finzi A; Sodroski J
J Virol; 2022 Sep; 96(17):e0063622. PubMed ID: 35980207
[TBL] [Abstract][Full Text] [Related]
3. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
4. Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity.
Fritschi CJ; Anang S; Gong Z; Mohammadi M; Richard J; Bourassa C; Severino KT; Richter H; Yang D; Chen HC; Chiu TJ; Seaman MS; Madani N; Abrams C; Finzi A; Hendrickson WA; Sodroski JG; Smith AB
Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2222073120. PubMed ID: 36961924
[TBL] [Abstract][Full Text] [Related]
5. Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.
Zhao C; Princiotto AM; Nguyen HT; Zou S; Zhao ML; Zhang S; Herschhorn A; Farrell M; Pahil K; Melillo B; Sambasivarao SV; Abrams C; Smith AB; Madani N; Sodroski J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31391272
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Easterhoff D; Bradley T; Luo K; Williams WB; Liao HX; Moody MA; Phad GE; Vázquez Bernat N; Melillo B; Santra S; Smith AB; Karlsson Hedestam GB; Haynes B; Sodroski J
J Virol; 2016 May; 90(10):5031-5046. PubMed ID: 26962221
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.
Haim H; Si Z; Madani N; Wang L; Courter JR; Princiotto A; Kassa A; DeGrace M; McGee-Estrada K; Mefford M; Gabuzda D; Smith AB; Sodroski J
PLoS Pathog; 2009 Apr; 5(4):e1000360. PubMed ID: 19343205
[TBL] [Abstract][Full Text] [Related]
9. Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.
Zou S; Zhang S; Gaffney A; Ding H; Lu M; Grover JR; Farrell M; Nguyen HT; Zhao C; Anang S; Zhao M; Mohammadi M; Blanchard SC; Abrams C; Madani N; Mothes W; Kappes JC; Smith AB; Sodroski J
J Virol; 2020 May; 94(10):. PubMed ID: 32161177
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates.
Matsumoto K; Kuwata T; Tolbert WD; Richard J; Ding S; Prévost J; Takahama S; Judicate GP; Ueno T; Nakata H; Kobayakawa T; Tsuji K; Tamamura H; Smith AB; Pazgier M; Finzi A; Matsushita S
J Virol; 2023 Jan; 97(1):e0163822. PubMed ID: 36511698
[TBL] [Abstract][Full Text] [Related]
11. Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.
Richard J; Pacheco B; Gohain N; Veillette M; Ding S; Alsahafi N; Tolbert WD; Prévost J; Chapleau JP; Coutu M; Jia M; Brassard N; Park J; Courter JR; Melillo B; Martin L; Tremblay C; Hahn BH; Kaufmann DE; Wu X; Smith AB; Sodroski J; Pazgier M; Finzi A
EBioMedicine; 2016 Oct; 12():208-218. PubMed ID: 27633463
[TBL] [Abstract][Full Text] [Related]
12. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of coreceptor recognition by HIV-1 envelope spike.
Shaik MM; Peng H; Lu J; Rits-Volloch S; Xu C; Liao M; Chen B
Nature; 2019 Jan; 565(7739):318-323. PubMed ID: 30542158
[TBL] [Abstract][Full Text] [Related]
14. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
Hill CM; Deng H; Unutmaz D; Kewalramani VN; Bastiani L; Gorny MK; Zolla-Pazner S; Littman DR
J Virol; 1997 Sep; 71(9):6296-304. PubMed ID: 9261346
[TBL] [Abstract][Full Text] [Related]
15. Cryo-EM structures of HIV-1 trimer bound to CD4-mimetics BNM-III-170 and M48U1 adopt a CD4-bound open conformation.
Jette CA; Barnes CO; Kirk SM; Melillo B; Smith AB; Bjorkman PJ
Nat Commun; 2021 Mar; 12(1):1950. PubMed ID: 33782388
[TBL] [Abstract][Full Text] [Related]
16. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.
Brower ET; Schön A; Freire E
Biochemistry; 2010 Mar; 49(11):2359-67. PubMed ID: 20166763
[TBL] [Abstract][Full Text] [Related]
17. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM
Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
[TBL] [Abstract][Full Text] [Related]
19. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation.
Tran EE; Borgnia MJ; Kuybeda O; Schauder DM; Bartesaghi A; Frank GA; Sapiro G; Milne JL; Subramaniam S
PLoS Pathog; 2012; 8(7):e1002797. PubMed ID: 22807678
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
